Helix BioPharma Corp. has announced the voting results from its Annual General and Special Meeting of Shareholders held on January 30, 2026. A total of 61,885,815 common shares were voted at the meeting, representing 81.03% of the company's total issued and outstanding shares. Shareholders voted overwhelmingly in favor of all items of business, with approval rates consistently at 99.99% across all resolutions.
The four director nominees listed in Helix's Management Information Circular dated December 15, 2025, were re-elected to serve for the ensuing year. Jacek Antas, Jerzy Leszczynski, Janusz Grabski, and Malgorzata Laube each received 99.99% support from voting shareholders. The resolution to appoint Clearhouse LLP as auditor of Helix BioPharma until the next annual general meeting was also approved with 99.99% of votes cast in favor.
A significant resolution approved at the meeting authorizes an amendment to the company's articles to effect a consolidation of issued and outstanding common shares. The consolidation could occur on a basis of up to five pre-consolidation shares for one post-consolidation share, with the board authorized to determine the final ratio at its discretion. This resolution received 99.99% approval from voting shareholders.
The voting results indicate strong shareholder confidence in Helix's current leadership and strategic direction as the company advances its oncology pipeline. Helix BioPharma is a clinical-stage oncology company developing novel therapies for hard-to-treat cancers, with its pipeline spearheaded by a proprietary technology platform of bio-conjugates targeting CEACAM6-expressing solid tumors. The company's lead candidate, L-DOS47, has completed Phase Ib studies in non-small cell lung cancer.
The share consolidation authorization provides the company with flexibility to potentially improve its capital structure and market position. Such consolidations are often pursued by companies seeking to meet stock exchange listing requirements, attract institutional investors, or create a more favorable perception in financial markets. The board's discretion in determining the final ratio allows for strategic timing based on market conditions and corporate needs.
A report on all items of business voted at the meeting will be filed on SEDAR+ at https://www.sedarplus.com. The company is listed on multiple exchanges, including the TSX under symbol "HBP," OTC PINK under "HBPCD," and FWB under "HBP0." Additional information about the company is available through its corporate website at https://www.helixbiopharma.com.
The overwhelming shareholder support for all resolutions suggests alignment between management and investors regarding the company's strategic direction. For the biotechnology sector, such strong governance approval can signal stability to potential partners and investors as Helix continues developing its oncology pipeline. The share consolidation authority could position the company more favorably for future financing opportunities or strategic transactions as it advances its clinical programs.
